Niktimvo
Incyte and Syndax Secure FDA Approval for Niktimvo, a Breakthrough Treatment for Chronic Graft-Versus-Host Disease
Incyte, Syndax, Niktimvo, FDA approval, graft-versus-host disease, GVHD, axatilimab-csfr, chronic GVHD, allogeneic stem cell transplant